Join the conversation:

Who we are

Halozyme Therapeutics

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, oncology, dermatology, and drug delivery markets. The company's product portfolio is primarily based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix.

Halozyme's ENHANZE™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Pfizer and Baxter, to apply ENHANZE technology to biological therapeutics, including immunoglobulin, Herceptin® and MabThera®. Halozyme’s Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target significant areas of unmet medical need.

What's new


On March 28th Halozyme announced that
the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in September 2013, this is the second European approval for a novel subcutaneous formulation of one of Roche’s oncology products using Halozyme’s patented EnhanzeTM (recombinant human hyaluronidase) technology.